PHARNEXT (EPA:ALPHA) Pharnext enters the final stretch for the signature of a licensing agreement for its drug candidate in Charcot Marie Tooth disease type 1A, enabling it to capitalize on its assets and put an end to the OCEANE BSA financing line
Transparency directive : regulatory news
20/09/2023 08:30
PHARNEXT's latest news
28/02/2024 08:30
19/12/2023 08:00
11/12/2023 08:30
27/11/2023 08:30
23/11/2023 08:30
26/09/2023 10:30
20/09/2023 08:30
24/08/2023 08:30
12/05/2023 08:30
23/03/2023 08:30
Other stories
29/04/2024 06:38
29/04/2024 06:27
29/04/2024 07:00
29/04/2024 03:04
29/04/2024 08:31
29/04/2024 05:47
28/04/2024 22:33
28/04/2024 13:00
29/04/2024 00:47
28/04/2024 19:14
28/04/2024 19:10
29/04/2024 04:17
28/04/2024 16:26
28/04/2024 15:33
29/04/2024 01:01
28/04/2024 15:58
28/04/2024 20:01
29/04/2024 04:43
28/04/2024 14:59
29/04/2024 00:32
29/04/2024 02:00
28/04/2024 08:02
28/04/2024 20:02
29/04/2024 01:01
29/04/2024 00:05
29/04/2024 07:00
28/04/2024 23:41
28/04/2024 22:30
29/04/2024 05:03
29/04/2024 08:31
28/04/2024 22:44
29/04/2024 08:08
27/04/2024 20:48
27/04/2024 21:03
A new era: Ariane 6 maiden launch campaign gets underway - NASASpaceFlight.com - NASASpaceflight.com
28/04/2024 12:18
28/04/2024 08:51
27/04/2024 13:26
29/04/2024 00:00